4578.T4578.T

4578.T is engaged in oncology and psychiatry research. In oncology, LONSURF has been studied, with findings from the RECOURSE, TAGS, and SUNLIGHT trials. Safety findings for LONSURF include neutropenia (all grades) at 67% in RECOURSE and 66% in TAGS, and neutropenia (Grades 3-4) at 38% in both RECOURSE and TAGS. Anemia (Grades 3-4) was observed at 18% in RECOURSE and 19% in TAGS. Thrombocytopenia (all grades) was 42% in RECOURSE and 34% in TAGS, with Grades 3-4 thrombocytopenia at 5% in RECOURSE and 6% in TAGS. Infections (all grades) were reported at 23% in TAGS, with 5% being Grades 3-4. Other adverse events for LONSURF in TAGS included nausea (all grades) at 37% and vomiting (all grades) at 25%. In the SUNLIGHT trial, neutrophils decreased (all grades) at 68% and hemoglobin decreased (all grades) at 73%.

In psychiatry, brexpiprazole has been investigated. In Study 331-12-283, 80% of subjects exhibited comorbid irritability or aberrant motor behavior. Study 331-14-213 reported 85% of subjects with irritability/lability. The incidence of irritability in long-term open-label trials for all Brex was 2.2%, and 0.8% in long-term adult schizophrenia trials. The total incidence of irritability was 2.0%. Mortality risk for brexpiprazole versus placebo was 4.16 over a 114-day sampling period and 4.75 across all deaths in Phase 3 studies. In short-term controlled trials, the incidence of akathisia was 4.2% for all Brex compared to 2.6% for placebo, and headache incidence was 5.9% for all Brex versus 4.3% for placebo.